An 'earth-shattering' lung cancer pill can slash the risk of the disease returning by more than 70 per cent and cut the likelihood of dying within five years of treatment in half, research shows.Striking data, recently published in the , have led cancer specialists to refer to the drug, called osimertinib, as 'groundbreaking'.The pill is approved by US drug chiefs for those with a genetic subtype of , which affects some 60,000 patients.
Load More
Load More